Cargando…

In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli

E. coli is a Gram-negative bacterium that causes different human infections. Additionally, it resists common antibiotics due to its outer protective membrane. Natural products have been proven to be efficient antibiotics. However, plant natural products are far less explored in this regard. Accordin...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhadrami, Hani A., Abdulaal, Wesam H., Hassan, Hossam M., Alhakamy, Nabil A., Sayed, Ahmed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778091/
https://www.ncbi.nlm.nih.gov/pubmed/35056143
http://dx.doi.org/10.3390/ph15010086
_version_ 1784637234557747200
author Alhadrami, Hani A.
Abdulaal, Wesam H.
Hassan, Hossam M.
Alhakamy, Nabil A.
Sayed, Ahmed M.
author_facet Alhadrami, Hani A.
Abdulaal, Wesam H.
Hassan, Hossam M.
Alhakamy, Nabil A.
Sayed, Ahmed M.
author_sort Alhadrami, Hani A.
collection PubMed
description E. coli is a Gram-negative bacterium that causes different human infections. Additionally, it resists common antibiotics due to its outer protective membrane. Natural products have been proven to be efficient antibiotics. However, plant natural products are far less explored in this regard. Accordingly, over 16,000 structures covering almost all African medicinal plants in AfroDb in a structural-based virtual screening were used to find efficient anti-E. coli candidates. These drug-like structures were docked into the active sites of two important molecular targets (i.e., E. coli’s Ddl-B and Gyr-B). The top-scoring hits (i.e., got docking scores < −10 kcal/mol) produced in the initial virtual screening (0.15% of the database structures for Ddl-B and 0.17% of the database structures for Gyr-B in the database) were further refined using molecular dynamic simulation-based binding free energy (ΔG) calculation. Anthraquinones were found to prevail among the retrieved hits. Accordingly, readily available anthraquinone derivatives (10 hits) were selected, prepared, and tested in vitro against Ddl-B, Gyr-B, multidrug-resistant (MDR) E. coli, MRSA, and VRSA. A number of the tested derivatives demonstrated strong micromolar enzyme inhibition and antibacterial activity against E. coli, MRSA, and VRSA, with MIC values ranging from 2 to 64 µg/mL. Moreover, both E. coli’s Ddl-B and Gyr-B were inhibited by emodin and chrysophanol with IC(50) values comparable to the reference inhibitors (IC(50) = 216 ± 5.6, 236 ± 8.9 and 0.81 ± 0.3, 1.5 ± 0.5 µM for Ddl-B and Gyr-B, respectively). All of the active antibacterial anthraquinone hits showed low to moderate cellular cytotoxicity (CC(50) > 50 µM) against human normal fibroblasts (WI-38). Furthermore, molecular dynamic simulation (MDS) experiments were carried out to reveal the binding modes of these inhibitors inside the active site of each enzyme. The findings presented in this study are regarded as a significant step toward developing novel antibacterial agents against MDR strains.
format Online
Article
Text
id pubmed-8778091
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87780912022-01-22 In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli Alhadrami, Hani A. Abdulaal, Wesam H. Hassan, Hossam M. Alhakamy, Nabil A. Sayed, Ahmed M. Pharmaceuticals (Basel) Article E. coli is a Gram-negative bacterium that causes different human infections. Additionally, it resists common antibiotics due to its outer protective membrane. Natural products have been proven to be efficient antibiotics. However, plant natural products are far less explored in this regard. Accordingly, over 16,000 structures covering almost all African medicinal plants in AfroDb in a structural-based virtual screening were used to find efficient anti-E. coli candidates. These drug-like structures were docked into the active sites of two important molecular targets (i.e., E. coli’s Ddl-B and Gyr-B). The top-scoring hits (i.e., got docking scores < −10 kcal/mol) produced in the initial virtual screening (0.15% of the database structures for Ddl-B and 0.17% of the database structures for Gyr-B in the database) were further refined using molecular dynamic simulation-based binding free energy (ΔG) calculation. Anthraquinones were found to prevail among the retrieved hits. Accordingly, readily available anthraquinone derivatives (10 hits) were selected, prepared, and tested in vitro against Ddl-B, Gyr-B, multidrug-resistant (MDR) E. coli, MRSA, and VRSA. A number of the tested derivatives demonstrated strong micromolar enzyme inhibition and antibacterial activity against E. coli, MRSA, and VRSA, with MIC values ranging from 2 to 64 µg/mL. Moreover, both E. coli’s Ddl-B and Gyr-B were inhibited by emodin and chrysophanol with IC(50) values comparable to the reference inhibitors (IC(50) = 216 ± 5.6, 236 ± 8.9 and 0.81 ± 0.3, 1.5 ± 0.5 µM for Ddl-B and Gyr-B, respectively). All of the active antibacterial anthraquinone hits showed low to moderate cellular cytotoxicity (CC(50) > 50 µM) against human normal fibroblasts (WI-38). Furthermore, molecular dynamic simulation (MDS) experiments were carried out to reveal the binding modes of these inhibitors inside the active site of each enzyme. The findings presented in this study are regarded as a significant step toward developing novel antibacterial agents against MDR strains. MDPI 2022-01-11 /pmc/articles/PMC8778091/ /pubmed/35056143 http://dx.doi.org/10.3390/ph15010086 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Alhadrami, Hani A.
Abdulaal, Wesam H.
Hassan, Hossam M.
Alhakamy, Nabil A.
Sayed, Ahmed M.
In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title_full In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title_fullStr In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title_full_unstemmed In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title_short In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
title_sort in silico-based discovery of natural anthraquinones with potential against multidrug-resistant e. coli
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778091/
https://www.ncbi.nlm.nih.gov/pubmed/35056143
http://dx.doi.org/10.3390/ph15010086
work_keys_str_mv AT alhadramihania insilicobaseddiscoveryofnaturalanthraquinoneswithpotentialagainstmultidrugresistantecoli
AT abdulaalwesamh insilicobaseddiscoveryofnaturalanthraquinoneswithpotentialagainstmultidrugresistantecoli
AT hassanhossamm insilicobaseddiscoveryofnaturalanthraquinoneswithpotentialagainstmultidrugresistantecoli
AT alhakamynabila insilicobaseddiscoveryofnaturalanthraquinoneswithpotentialagainstmultidrugresistantecoli
AT sayedahmedm insilicobaseddiscoveryofnaturalanthraquinoneswithpotentialagainstmultidrugresistantecoli